Varenicline (marketed as Chantix® for smoking cessation) is being investigated in this Phase 2 randomized controlled trial as a potential treatment to reduce falls in Parkinson's disease patients who have significant cholinergic denervation. The trial specifically enrolls patients with hypocholinergic status, defined by reduced acetylcholine signaling in the occipital association cortex as measured by F-fluoroethoxybenzovesamicol (FEOBV) PET imaging[1].
Falls are a major source of morbidity in Parkinson's disease, affecting up to 60% of patients annually. Current treatment options are limited, with most approaches targeting dopaminergic pathways rather than the cholinergic deficits that contribute to balance and gait dysfunction. Varenicline's action as a partial agonist at alpha-7 nicotinic acetylcholine receptors (alpha-7 nAChR) offers a novel mechanism to address this gap[2].
| Attribute | Details |
|---|---|
| NCT Number | NCT06679374 |
| Title | Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease |
| Phase | Phase 2 |
| Status | Recruiting |
| Sponsor | Vikas Kotagal (Investigator-initiated) |
| Participants | 102 |
| Start Date | April 9, 2025 |
| Estimated Completion | January 2027 |
| Intervention | Varenicline vs. Placebo |
| Duration | 12 months |
Varenicline is a partial agonist at the alpha-7 subtype of nicotinic acetylcholine receptors (nAChRs). These receptors are widely expressed in the brain, including in regions critical for attention, sensory processing, and motor control[3].
Why alpha-7 nAChR for falls in PD:
Cognitive-motor integration: The alpha-7 nAChR is highly expressed in brain regions involved in attention and sensorimotor integration, including the occipital association cortex. Optimal falls prevention requires integrating visual-spatial information with motor output — a process dependent on intact cholinergic signaling.
Postural control: Cholinergic neurons from the basal forebrain project to cortical areas involved in postural stability. Loss of these projections in PD impairs the ability to adapt gait to environmental demands.
Dual-task performance: The trial's primary endpoint (normal pace-dual task cost, npDTC) specifically measures the interference between walking and a concurrent cognitive task. Cholinergic enhancement via alpha-7 nAChR agonism has been shown to improve dual-task performance in PD[4].
Non-dopaminergic approach: Unlike standard PD medications, varenicline does not target dopamine pathways. This is important because dopaminergic medications do not reliably prevent falls — many patients on optimal dopaminergic therapy still experience significant fall risk due to non-dopaminergic deficits.
| Property | Value |
|---|---|
| Primary Target | Alpha-7 nAChR (partial agonist) |
| Secondary Target | Alpha-4-beta-2 nAChR (partial agonist) |
| Bioavailability | ~90% (oral) |
| Half-life | ~24 hours |
| Approved Use | Smoking cessation (0.5 mg and 1 mg tablets) |
| Standard Dosing | Titrated from 0.5 mg BID to 1 mg BID over 1 week |
For the PD trial, varenicline dosing follows a similar titration schedule to the approved smoking cessation regimen, reaching therapeutic doses within the first week.
The trial's enrollment criteria require participants to have occipital association cortex cholinergic denervation in the lowest tertile of the normal range on FEOBV PET. This imaging biomarker provides a direct measure of cholinergic terminal density[5].
FEOBV PET background:
| Measure | Description |
|---|---|
| Normal Pace-Dual Task Cost (npDTC) | Change from baseline to 12 months in the difference between single-task normal pace gait speed and dual-task gait speed. Lower npDTC indicates less interference from the cognitive task, suggesting better gait automaticity and reduced fall risk. |
The dual-task paradigm assesses how much a person's gait is disrupted when simultaneously performing a cognitive task (e.g., serial sevens or verbal fluency). In PD, this dual-task cost is exaggerated due to competing demands on limited attentional resources. Cholinergic enhancement should reduce this interference.
| Measure | Description |
|---|---|
| Number of falls | Total count of falls from first dose to 12-month visit, assessed via fall diaries and monthly phone calls |
Falls are defined as an unintentional descent to the floor, ground, or lower level. The fall count provides a direct clinical endpoint that is highly meaningful to patients and caregivers.
Falls in PD have multiple contributing factors:
Cholinergic augmentation addresses multiple pathways simultaneously: improving attention for environmental hazard detection, enhancing sensorimotor integration for rapid postural corrections, and supporting the automaticity of gait[6].
Varenicline was selected because:
Unlike donepezil or rivastigmine (acetylcholinesterase inhibitors that boost acetylcholine non-selectively), varenicline provides targeted agonism at specific nAChR subtypes. This mechanistic distinction may offer advantages:
However, both approaches share the goal of enhancing cholinergic transmission in the brain.
The basal forebrain contains large neurons that synthesize acetylcholine via choline acetyltransferase (ChAT) and project throughout the cortex. These cholinergic projections are critical for:
In Parkinson's disease, these cholinergic neurons degenerate alongside dopaminergic neurons, contributing to both motor and non-motor symptoms[6:1].
The pedunculopontine nucleus (PPN) is a brainstem structure with cholinergic neurons that project to thalamic and spinal cord targets. PPN cholinergic dysfunction contributes to:
Varenicline's primary mechanism is cortical rather than brainstem, but cortical cholinergic enhancement may indirectly improve brainstem function through top-down modulation.
FEOBV PET provides a quantitative measure of cholinergic terminal density across cortical regions. Studies have shown:
ClinicalTrials.gov. NCT06679374: Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease. ↩︎
Cholinergic neurotransmission underlying visual hallucinations in Parkinson's disease: Integration of multimodal evidence and translational approaches. CNS Neurosci Ther. 2024. ↩︎
Varenicline: a alpha-7 nicotinic acetylcholine receptor agonist for smoking cessation. CNS Drug Rev. 2007. ↩︎
Dual-task cost in Parkinson disease: association with falls and cholinergic integrity. Neurology. 2021. ↩︎
FEOBV PET imaging of cortical cholinergic denervation in Parkinson's disease. Neurology. 2022. ↩︎
Selective loss of cholinergic neurons in PD: implications for non-motor symptoms. Mov Disord. 2024. ↩︎ ↩︎